Skip to content

Study · In vitro (cells) · 2021

2 results

Recurrent non-severe hypoglycemia aggravates cognitive decline in diabetes and induces mitochondrial dysfunction in cultured astrocytes.

Gao R, Ren L, Zhou Y, Wang L, Xie Y, Zhang M, Liu X, Ke S, Wu K, Zheng J, Liu X, Chen Z, Liu L

Molecular and cellular endocrinology2 Feb 2021Cited by 21 (Europe PMC)

PMID33545179 (opens in a new tab)DOI10.1016/j.mce.2021.111192 (opens in a new tab)PepBankPUB-33545179
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In high-glucose cultured astrocytes, SS‑31 reversed the cell viability defects caused by recurrent low glucose.

    In plain wordsIn cultured brain support cells, SS‑31 reversed the loss of cell viability caused by repeated low glucose.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCell viability under recurrent low glucose
    Study

    n: not reported in source

    Cultured astrocytes in high glucose with recurrent low glucose (RLG)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 mediated protection of mitochondrial functions reversed RLG-induced cell viability defects and neurotrophin production.
    1 context sentence
    Summary · context
    In vitro, recurrent low glucose (RLG)3 impaired cell viability and induced apoptosis of high-glucose cultured astrocytes.
  2. 02LabIn vitro (cells)Efficacy outcome

    In high-glucose cultured astrocytes, SS‑31 reversed the reduction in neurotrophin production caused by recurrent low glucose.

    In plain wordsIn cultured brain support cells, SS‑31 reversed the drop in growth-factor production caused by repeated low glucose.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseNeurotrophin production under recurrent low glucose
    Study

    n: not reported in source

    Cultured astrocytes in high glucose with recurrent low glucose (RLG)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 mediated protection of mitochondrial functions reversed RLG-induced cell viability defects and neurotrophin production.
    1 context sentence
    Summary · context
    In vitro, recurrent low glucose (RLG)3 impaired cell viability and induced apoptosis of high-glucose cultured astrocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.